Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults.

Guler HP, Zapf J, Froesch ER

The New England journal of medicine1 Jul 1987Cited by 328 (Europe PMC)

PMID3299085DOI10.1056/nejm198707163170303PepBankPUB-03299085

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanNon-randomized trialEfficacy outcome
In healthy volunteers, IGF I and insulin produced nearly identical hypoglycemic responses, with lowest glucose 1.98 mmol per liter after IGF I and 1.78 after insulin at 30 minutes.
In plain wordsIn healthy volunteers, IGF I and insulin lowered blood sugar by nearly the same amount at the tested doses.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeBlood glucose lowering (hypoglycemic response) versus insulin
Study
n = 8
Comparator
Insulin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 micrograms per kilogram of body weight · intravenous injectionAs given in this study (human).
Measurements
Lowest blood glucose
1.98 mmol per liter
after IGF I, 30 minutes
Lowest blood glucose
1.78 mmol per liter
after insulin, 30 minutes
Lowest blood glucose reported +/- uncertainty (type not stated)
0.44 mmol per liter
after IGF I, 30 minutes
Lowest blood glucose reported +/- uncertainty (type not stated)
0.29 mmol per liter
after insulin, 30 minutes
Source sentences
Summary
The hypoglycemic responses to both hormones were nearly identical in the doses used.
Summary
The lowest blood glucose levels were reached after 30 minutes: 1.98 +/- 0.44 mmol per liter after IGF I and 1.78 +/- 0.29 after insulin.
1 context sentence(design, population, supporting numbers)
Summary · context
We compared the short-term metabolic effects of recombinant IGF I (100 micrograms [13.3 nmol] per kilogram of body weight) and insulin (0.15 IU [1 nmol] per kilogram) in eight healthy volunteers (four men and four women).
Report a problemFND-0329908501
02HumanNon-randomized trialActivity measurement
In healthy volunteers, IGF I had 6 percent of insulin's molar potency for producing hypoglycemia.
In plain wordsIn healthy volunteers, IGF I was less potent than insulin per molecule for producing low blood sugar.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseMolar hypoglycemic potency
Study
n = 8
Comparator
Insulin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 micrograms per kilogram of body weight · intravenous injectionAs given in this study (human).
Measurements
Molar hypoglycemic potency relative to insulin
6 percent
molar basis, production of hypoglycemia
Source sentences
Summary
On a molar basis, IGF I was only 6 percent as potent as insulin in the production of hypoglycemia.
1 context sentence(design, population, supporting numbers)
Summary · context
We compared the short-term metabolic effects of recombinant IGF I (100 micrograms [13.3 nmol] per kilogram of body weight) and insulin (0.15 IU [1 nmol] per kilogram) in eight healthy volunteers (four men and four women).
Report a problemFND-0329908503
03HumanNon-randomized trialEfficacy outcome
In healthy volunteers, IGF I inhibited lipolysis less effectively than insulin.
In plain wordsIn healthy volunteers, IGF I blocked fat breakdown less effectively than insulin.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseLipolysis inhibition
Study
n = 8
Comparator
Insulin
Outcome group
Lipids · Metabolic and weight
Studied dose
100 micrograms per kilogram of body weight · intravenous injectionAs given in this study (human).
Source sentences
Summary
Insulin also inhibited lipolysis more effectively than IGF I.
1 context sentence(design, population, supporting numbers)
Summary · context
We compared the short-term metabolic effects of recombinant IGF I (100 micrograms [13.3 nmol] per kilogram of body weight) and insulin (0.15 IU [1 nmol] per kilogram) in eight healthy volunteers (four men and four women).
Report a problemFND-0329908504
04HumanNon-randomized trialEfficacy outcome
In healthy volunteers, epinephrine responded similarly to IGF I and insulin.
In plain wordsIn healthy volunteers, epinephrine responded similarly to IGF I and insulin.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeEpinephrine response
Study
n = 8
Comparator
Insulin
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
100 micrograms per kilogram of body weight · intravenous injectionAs given in this study (human).
Source sentences
Summary
Levels of epinephrine, norepinephrine, growth hormone, glucagon, and cortisol responded similarly to both agents.
1 context sentence(design, population, supporting numbers)
Summary · context
We compared the short-term metabolic effects of recombinant IGF I (100 micrograms [13.3 nmol] per kilogram of body weight) and insulin (0.15 IU [1 nmol] per kilogram) in eight healthy volunteers (four men and four women).
Report a problemFND-0329908505
05HumanNon-randomized trialEfficacy outcome
In healthy volunteers, norepinephrine responded similarly to IGF I and insulin.
In plain wordsIn healthy volunteers, norepinephrine responded similarly to IGF I and insulin.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeNorepinephrine response
Study
n = 8
Comparator
Insulin
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
100 micrograms per kilogram of body weight · intravenous injectionAs given in this study (human).
Source sentences
Summary
Levels of epinephrine, norepinephrine, growth hormone, glucagon, and cortisol responded similarly to both agents.
1 context sentence(design, population, supporting numbers)
Summary · context
We compared the short-term metabolic effects of recombinant IGF I (100 micrograms [13.3 nmol] per kilogram of body weight) and insulin (0.15 IU [1 nmol] per kilogram) in eight healthy volunteers (four men and four women).
Report a problemFND-0329908506
06HumanNon-randomized trialEfficacy outcome
In healthy volunteers, GH responded similarly to IGF I and insulin.
In plain wordsIn healthy volunteers, growth hormone responded similarly to IGF I and insulin.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeGH response
Study
n = 8
Comparator
Insulin
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
100 micrograms per kilogram of body weight · intravenous injectionAs given in this study (human).
Source sentences
Summary
Levels of epinephrine, norepinephrine, growth hormone, glucagon, and cortisol responded similarly to both agents.
1 context sentence(design, population, supporting numbers)
Summary · context
We compared the short-term metabolic effects of recombinant IGF I (100 micrograms [13.3 nmol] per kilogram of body weight) and insulin (0.15 IU [1 nmol] per kilogram) in eight healthy volunteers (four men and four women).
Report a problemFND-0329908507
07HumanNon-randomized trialEfficacy outcome
In healthy volunteers, glucagon responded similarly to IGF I and insulin.
In plain wordsIn healthy volunteers, glucagon responded similarly to IGF I and insulin.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeGlucagon response
Study
n = 8
Comparator
Insulin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 micrograms per kilogram of body weight · intravenous injectionAs given in this study (human).
Source sentences
Summary
Levels of epinephrine, norepinephrine, growth hormone, glucagon, and cortisol responded similarly to both agents.
1 context sentence(design, population, supporting numbers)
Summary · context
We compared the short-term metabolic effects of recombinant IGF I (100 micrograms [13.3 nmol] per kilogram of body weight) and insulin (0.15 IU [1 nmol] per kilogram) in eight healthy volunteers (four men and four women).
Report a problemFND-0329908508
08HumanNon-randomized trialEfficacy outcome
In healthy volunteers, cortisol responded similarly to IGF I and insulin.
In plain wordsIn healthy volunteers, cortisol responded similarly to IGF I and insulin.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeCortisol response
Study
n = 8
Comparator
Insulin
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
100 micrograms per kilogram of body weight · intravenous injectionAs given in this study (human).
Source sentences
Summary
Levels of epinephrine, norepinephrine, growth hormone, glucagon, and cortisol responded similarly to both agents.
1 context sentence(design, population, supporting numbers)
Summary · context
We compared the short-term metabolic effects of recombinant IGF I (100 micrograms [13.3 nmol] per kilogram of body weight) and insulin (0.15 IU [1 nmol] per kilogram) in eight healthy volunteers (four men and four women).
Report a problemFND-0329908509
09HumanNon-randomized trialPharmacokinetics
In healthy volunteers, serum IGF I increased from 144 +/- 38 to 424 +/- 56 ng per milliliter after injection.
In plain wordsIn healthy volunteers, blood IGF I increased after injection.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseSerum IGF I after injection
Study
n = 8
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
100 micrograms per kilogram of body weight · intravenous injectionAs given in this study (human).
Measurements
Serum IGF I
144 ng per milliliter
baseline
Serum IGF I
424 ng per milliliter
15 minutes after injection
Serum IGF I reported +/- uncertainty (type not stated)
38 ng per milliliter
baseline, parent serum IGF I value 144 ng per milliliter
Serum IGF I reported +/- uncertainty (type not stated)
56 ng per milliliter
15 minutes after injection, parent serum IGF I value 424 ng per milliliter
Source sentences
Summary
Fifteen minutes after injection, the serum level of IGF I increased from 144 +/- 38 ng per milliliter at base line to 424 +/- 56, of which 80 percent was free in the plasma (not bound to IGF carrier proteins).
1 context sentence(design, population, supporting numbers)
Summary · context
We compared the short-term metabolic effects of recombinant IGF I (100 micrograms [13.3 nmol] per kilogram of body weight) and insulin (0.15 IU [1 nmol] per kilogram) in eight healthy volunteers (four men and four women).
Report a problemFND-0329908510
10HumanNon-randomized trialPharmacokinetics
In healthy volunteers, 80 percent of plasma IGF I was free fifteen minutes after injection.
In plain wordsIn healthy volunteers, most plasma IGF I was unbound shortly after injection.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableFree plasma fraction
Study
n = 8
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
100 micrograms per kilogram of body weight · intravenous injectionAs given in this study (human).
Measurements
Free fraction of plasma IGF I
80 percent
15 minutes after injection
Source sentences
Summary
Fifteen minutes after injection, the serum level of IGF I increased from 144 +/- 38 ng per milliliter at base line to 424 +/- 56, of which 80 percent was free in the plasma (not bound to IGF carrier proteins).
1 context sentence(design, population, supporting numbers)
Summary · context
We compared the short-term metabolic effects of recombinant IGF I (100 micrograms [13.3 nmol] per kilogram of body weight) and insulin (0.15 IU [1 nmol] per kilogram) in eight healthy volunteers (four men and four women).
Report a problemFND-0329908511

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.